---
title: Lit Review Aspergillus
layout: page
---

#### Aspergillus

-------------------------------------------------

**Walsh, T. J. et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases 46, 327–360 (2008)**. [Full Text](http://cid.oxfordjournals.org/content/46/3/327.1.full)

--------------------------------------------------

**Herbrecht, R. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408–415 (2002).** [Full Text](http://www.nejm.org/doi/full/10.1056/NEJMoa020191)

Randomized unblinded trial. Voriconazole (6 mg/kg/d \* 2 doses IV f/b 4 mg/kg/dose IV q12h \* >7 d f/b 200 mg PO bd) compared against amphotericin B deoxycholate in 277 patients with proven / probable aspergillosis.

At 12 weeks, successful outcomes in 52% [31% complete response, 21% partial response]  voriconazole group vs 31% amphotericin group [16% complete response, 15% partial response].

Survival rates at 12 weeks: 71% voriconazole group vs 58% amphotericin group.

Voriconazole group had fewer drug related adverse effects

----------------------------------------------

**Cornely, O. A. et al. Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Clinical Infectious Diseases 44, 1289–1297 (2007).** [Full Text](http://cid.oxfordjournals.org/content/44/10/1289)

Compared 10 mg/kg/day vs 3 mg/kg/day doses of liposomal amphotericin B.

No additional benefit with 10mg/kg/d dose and higher rates of nephrotoxicity.

-------------------------------------------

**Walsh, T. J. et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225–234 (2002).** [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/11807146)

Voriconazole shown to be an appropriate agent for empiric antifungal therapy in neutropenic patients when fever has not responded to broad-spectrum antibiotic therpy.

For caspofungin: [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/15459300)

------------------------------------------

**Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am. J. Med. 86, 668–672 (1989).** [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/2658574)

132 patients randomised to empiric amphotericin B vs no therapy.

Fever response: 69% (amphotericin B) vs 53% (no treatment)
Breakthrough (documented) fungal infections: 1 case(amphotericin B) vs 6 cases(no treatment)

No difference in survival among the two groups.

------------------------------------------

**Cornely, O. A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348–359 (2007).** [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/17251531)

Patients on chemotherapy for AML/Myelodysplastic syndrome: 304 patients (posaconazole group) vs 298(fluconazole[240] or itraconazole[58])


Proven or probable fungal infections: 2% (posaconazole) vs 8%(fluconazole/itraconazole), -6% absolute reduction, p<0.001
Invasive aspergillosis: 1%(posaconazole) vs 7%(fluconazole/itraconazole), p<0.001
Mortality: 16%(posaconazole) vs 22%(fluconazole/itraconazole), p=0.04
More treatment adverse effects in posaconazole group.

Similar trial of prophylaxis (posaconazole vs fluconazole) in patients with GVHD. [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/17251530)

-------------------------------------------

**Stevens, D. A. et al. A Randomized Trial of Itraconazole in Allergic Bronchopulmonary Aspergillosis. New England Journal of Medicine 342, 756–762 (2000).** [Pubmed](http://www.ncbi.nlm.nih.gov/pubmed/10717010)

Double-blind randomized control trial: Itraconazole 200 mg (n=28) vs placebo (n=27) for 16 weeks

Response (reduction in corticosteroid dose, decrease in serum IgE level, improvement in exercise tolerance / resolution of pulmonary infiltrates)

46% response in itraconazole group vs 19% in placebo group (p=0.04)

---------------------------
